Janus Henderson Group
CCCC icon

Janus Henderson Group’s C4 Therapeutics CCCC Stock Holding History

Janus Henderson Group’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,081
Closed -$34.7K – 2605
2023
Q1 		$34.7K Sell
11,081
-727,548
-98% -$4.28M ﹤0.01% 2673
2022
Q4 		$4.36M Sell
738,629
-898,865
-55% -$7.45M ﹤0.01% 893
2022
Q3 		$14.4M Buy
1,637,494
+787,894
+93% +$8.18M 0.01% 753
2022
Q2 		$6.41M Sell
849,600
-237,182
-22% -$2.09M ﹤0.01% 793
2022
Q1 		$26.4M Buy
1,086,782
+40,837
+4% +$992K 0.01% 683
2021
Q4 		$33.7M Sell
1,045,945
-2,943
-0.3% -$116K 0.01% 661
2021
Q3 		$46.9M Sell
1,048,888
-84,241
-7% -$3.61M 0.02% 571
2021
Q2 		$42.9M Sell
1,133,129
-162,461
-13% -$5.82M 0.02% 611
2021
Q1 		$46.5M Sell
1,295,590
-2,019
-0.2% -$80.3K 0.02% 572
2020
Q4 		$40.4M Buy
+1,297,609
New +$37.6M 0.02% 593

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Janus Henderson Group's CCCC Position: Q2 2023 in Review

Janus Henderson Group sold out of C4 Therapeutics (CCCC) in Q2 2023, closing a stake of 11,081 shares — an estimated $34.7K sold.

Janus Henderson Group first reported a position in CCCC in Q4 2020 and held it in 10 quarters. The position peaked at $46.9M in Q3 2021. 100 funds tracked by Wall St. Rank hold CCCC as of Q2 2023.

  • Janus Henderson Group reported no remaining C4 Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Janus Henderson Group sold 11,081 C4 Therapeutics shares in Q2 2023, an estimated $34.7K.
  • Janus Henderson Group first reported a position in C4 Therapeutics in Q4 2020 and held it in 10 quarters.
  • Janus Henderson Group's C4 Therapeutics position peaked at $46.9M in Q3 2021.
  • 100 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2023.

Based on Janus Henderson Group's 13F filing for Q2 2023, filed 14 Aug 2023.